About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Homocysteine and Heart Disease

Citation:

US Cardiology 2004;1(1):1-4

Preclinical Diagnosis and Risk Assessment of Atherosclerosis - At Birth? At Event? When is Best?

Citation:

European Cardiology 2011;7(3):164–6

Hypertension, New Insights and Implications for Management

New Trends and Developments in Patients with Severe Aortic Stenosis - Towards Optimal Treatment?

Citation:

European Cardiology 2009;5(2):81–4